Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
3.340
+0.030 (0.91%)
At close: Mar 5, 2026, 4:00 PM EST
3.380
+0.040 (1.20%)
After-hours: Mar 5, 2026, 6:52 PM EST
Acumen Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Acumen Pharmaceuticals stock have an average target of 7.50, with a low estimate of 4.00 and a high estimate of 11. The average target predicts an increase of 124.55% from the current stock price of 3.34.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 27, 2026.
Analyst Ratings
The average analyst rating for Acumen Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Maintains $4 → $7 | Strong Buy | Maintains | $4 → $7 | +109.58% | Jan 27, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $9 → $8 | Strong Buy | Maintains | $9 → $8 | +139.52% | Nov 18, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $10 → $9 | Strong Buy | Maintains | $10 → $9 | +169.46% | Aug 25, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $4 | Strong Buy | Initiates | $4 | +19.76% | Jun 17, 2025 |
| UBS | UBS | Strong Buy Maintains $6 → $4 | Strong Buy | Maintains | $6 → $4 | +19.76% | Mar 28, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.09
from -1.71
EPS Next Year
-1.68
from -2.09
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.95 | -0.90 | |
| Avg | -2.09 | -1.68 | |
| Low | -2.13 | -2.04 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.